The preventive effects of two nutraceuticals on experimentally induced acute synovitis.
Authors: van de Water E, Oosterlinck M, Dumoulin M, Korthagen N M, van Weeren P R, van den Broek J, Everts H, Pille F, van Doorn D A
Journal: Equine veterinary journal
Summary
# Editorial Summary: Preventive Nutraceuticals in Experimentally Induced Synovitis Anti-inflammatory nutraceuticals are widely recommended for managing equine joint disease, yet rigorous evidence supporting their use remains sparse. Van de Water and colleagues evaluated two novel nutraceutical formulations—a multi-ingredient supplement (AT) and collagen hydrolysate (HP)—against meloxicam and placebo in 24 Standardbred horses following controlled intra-articular lipopolysaccharide injection to induce acute synovitis. Both nutraceuticals significantly suppressed key inflammatory markers in synovial fluid, including total protein, nucleated cell counts and prostaglandin E2, matching or exceeding the anti-inflammatory effects of meloxicam, whilst neither treatment affected deeper markers of cartilage degradation (interleukin-6, glycosaminoglycans, collagen synthesis or matrix metalloproteinase activity). Whilst the experimental model failed to generate clinically meaningful lameness, these findings suggest that pre-emptive supplementation warrants investigation in naturally occurring joint disease scenarios where clinical signs may be more pronounced and the protective window more relevant to practitioners. Further work examining dosing schedules, treatment duration and efficacy in chronic versus acute presentations would help determine whether these nutraceuticals have genuine clinical utility beyond the experimental setting.
Read the full abstract on PubMed
Practical Takeaways
- •These two nutraceuticals show measurable anti-inflammatory effects in controlled synovitis conditions, suggesting potential preventive benefit, but clinical efficacy in field conditions remains unproven.
- •The lack of lameness in this model limits interpretation of practical significance—further studies in naturally occurring joint disease or more severe inflammation are needed before clinical recommendations can be made.
- •Both nutraceuticals were well-tolerated with no adverse effects observed, making them safe to trial in clinical practice pending larger field studies.
Key Findings
- •Both nutraceuticals (multi-ingredient supplement AT and collagen hydrolysate HP) significantly reduced synovial fluid total protein, TNCC, and PGE2 compared to placebo following LPS-induced synovitis.
- •Meloxicam (positive control) also significantly reduced synovial fluid TP, TNCC, and PGE2 compared to placebo.
- •No statistically significant differences were observed between treatment groups in IL-6, GAGs, CPII, or MMPs.
- •The experimental model induced biochemical synovitis but did not produce clinically detectable lameness in any group.